Israel’s aMoon leads $110 million funding round in SOPHiA GENETICS

The new funding aims to boost the medtech company’s penetration in both the U.S. and Asian markets

Israel-based life sciences venture capital firm aMoon led a $110 million series F financing round in Swiss Medtech company SOPHiA GENETICS, according to a company statement issued this weekend. Hitachi Ventures, the venture arm of Japan’s Hitachi Group co-led the round, which was also participated by Credit Suisse, Swisscom Ventures, Endeavour Vision, Generation Investment Management, and the Pictet group.

 

SOPHiA GENETICS operates in the field of medical data and has established the world’s largest data-driven medicine community network based on its universal and collaborative AI platform. Its network supports healthcare professionals by translating complex medical data into valuable clinical insights. According to the company's statement, the SOPHiA platform is used by over 1,000 healthcare institutions and has analyzed 600,000 genomic profiles. The new funding aims to boost the company’s penetration in both the U.S. and Asian markets.

 

aMoon partners. Photo: Guy Gilad

“The overall demand for data-driven medicine is rapidly growing, and the next step is to successfully combine multiple sources of data to better address clinicians’ needs,” Dr. Tomer Berkovitz, Partner & CFO of aMoon said. “With this shift, more complex data will be generated, and we believe that SOPHIA’s decentralized model will play a pivotal role in empowering health organizations to offer better patient care.”